Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05711862 · ClinicalTrials.gov registry record · Phase 2
The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder
A Phase 2 study, sponsored by The University of Texas Health Science Center, Houston.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT05711862 is a Phase 2 study that was terminated before completion, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 7 participants.
The verdict
NCT05711862, a Phase 2 study, was terminated before completion, sponsored by The University of Texas Health Science Center, Houston.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of SUVO on sleep, stress, and cue reactivity/craving and to evaluate the preliminary safety and side effects profile of suvorexant (SUVO)
Interventions
- DRUG Placebo
- DRUG suvorexant (SUVO)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-03-09 |
| Est. Completion | 2024-03-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05711862
The ClinicalTrials.gov registry entry for NCT05711862 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05711862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05711862 about?
NCT05711862 is a clinical study titled "The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder". The purpose of this study is to determine the effects of SUVO on sleep, stress, and cue reactivity/craving and to evaluate the preliminary safety and side effects profile of suvorexant (SUVO)
What is the current status of trial NCT05711862?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2023-03-09. Estimated completion is 2024-03-28.
What interventions are being tested in trial NCT05711862?
The interventions under investigation include: Placebo (DRUG), suvorexant (SUVO) (DRUG).
Who is sponsoring clinical trial NCT05711862?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.